To address tumor heterogeneity, Ma et al. developed a heterodimer that targets both PSMA and NTR1, which showed prominent uptake in NTR1-positive/PSMA-negative and PSMA-positive/NTR1-negative prostate cancer xenografts [66]. This evidence concerns the gene FOLH1 and prostate carcinoma.